Clinical trial
Brain Metastases In ErbB2-Positive Breast Cancer
NCT00437073 · GlaxoSmithKline, Industry · Terminated
Key facts
| NCT number | NCT00437073 |
|---|---|
| Title | Brain Metastases In ErbB2-Positive Breast Cancer |
| Official title | Study EGF107671 - a Phase II Study of Lapatinib Plus Topotecan or Lapatinib Plus Capecitabine in the Treatment of Recurrent Brain Metastases From ErbB2-Positive Breast Cancer Following Cranial Radiotherapy |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neoplasms, Breast |
| Intervention type | Drug |
| Interventions | capecitabine, topotecan, lapatinib |
| Enrollment | 22 |
| Start date | May 1, 2007 |
| Primary completion | Jan 1, 2009 |
| Completion | Feb 1, 2010 |
| First posted | Feb 19, 2007 |
| Last update posted | Oct 15, 2015 |
| Countries | Austria, Belgium, Canada, France, Germany, Greece, Israel, Italy, Spain, Sweden, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: